Heart Block: AV Conduction Problems, Degrees, Symptoms and Treatment

Direct answer. Atrioventricular heart block means that electrical signals are delayed or interrupted as they travel toward the ventricles. It is an electrical condition, not a blocked coronary artery. The degree and clinical effects matter: some mild findings require monitoring, while complete or symptomatic block can need urgent treatment and pacing.

Evidence summary

Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.

What it is

The atrioventricular pathway carries electrical signals from the upper toward the lower chambers. AV block delays or interrupts that communication. NHS distinguishes first-, second- and third-degree block. The report’s actual degree matters; the broad phrase “heart block” is not enough to identify severity. NHS heart block.

In complete, third-degree block, the usual atrial signals do not reach the ventricles. This can produce a very slow rhythm and serious symptoms. It differs from sinus-node dysfunction and from a bundle-branch delay farther along the conduction system. NHLBI conduction disorders.

How it works

The heart depends on coordinated electrical signals to organize filling and pumping. A transmission problem can change the relationship between atrial and ventricular activity. An ECG shows this relationship more directly than a pulse reading, which only describes the beats reaching the circulation. NHLBI conduction disorders.

Block can be present from birth or develop later, and medication or underlying cardiac problems can contribute. The clinical assessment should consider whether a finding is new, persistent or intermittent and whether symptoms occur at the same time. A suspected contributor is reviewed in the context of the whole treatment plan. NHLBI arrhythmia causes.

The evidence-based treatments

ECG establishes the electrical pattern, while selected monitoring can investigate intermittent block or symptoms. The clinician may also assess other cardiac or systemic factors. Ask for the exact degree and, where relevant, subtype rather than assuming that all second-degree findings mean the same thing. NHLBI arrhythmia diagnosis.

NHS describes different management according to severity. Some findings need observation, while more serious or symptomatic situations may require a pacemaker. Acute instability is a different setting from a planned long-term device discussion. NHS heart block.

The medication list matters because some drugs can affect conduction. A clinician can weigh the original reason for treatment against the documented electrical problem. Do not resolve this by stopping a prescription from an online interaction list. NHLBI arrhythmia treatment.

For a proposed pacemaker, ask which finding it addresses, how follow-up will work and what limitations remain. Pacing supports an electrical indication; it does not automatically treat every other heart or circulation problem. The guide does not rank brands or claim trial-level independence for all device outcomes.

Supplement and lifestyle evidence

Discuss individual triggers and safe activity with the care team. A general rhythm label is not enough to decide whether exercise, caffeine or another exposure should be restricted. Managing relevant heart disease and taking prescribed medicines appropriately can be part of the plan. NHLBI living with arrhythmia.

No supplement is established here as a treatment for atrioventricular heart block. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.

What works and what does not

Useful care names the exact AV-block finding, links it with symptoms where possible and identifies any contributor. It explains why observation, a treatment change or pacing is appropriate.

Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.

Risks and side effects

Fainting, chest pain, severe breathlessness or a markedly unwell state with a suspected slow rhythm needs urgent assessment. An unresponsive person not breathing normally requires the local emergency service immediately. NHS arrhythmia.

Medicines intended to change heart rate or rhythm can themselves cause troublesome symptoms or another rhythm problem. Procedures have risks that should be explained for the proposed intervention, including bleeding or damage associated with catheter procedures. The exact diagnosis, heart function and medicine combination matter. NHLBI arrhythmia treatment.

Important interactions

NHLBI notes that rate- and rhythm-changing drugs can worsen some conduction problems or cause another arrhythmia. Tell the prescriber about all medicines, supplements and recreational substances before adding a product or changing treatment. NHLBI arrhythmia treatment.

Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.

Who needs assessment

People with a new block finding, symptoms or medicine changes affecting conduction need the recommended clinical review. A report should explain whether the finding is mild, higher grade, intermittent or associated with another heart problem. NHS heart block.

A person with recurring symptoms needs a clear review route even when a brief earlier ECG was reassuring. Record the timing and circumstances for the clinician, rather than provoking another episode to prove what it is. NHLBI arrhythmia diagnosis.

Clinician-led use and follow-up

Ask what the tracing showed, whether further monitoring is pending and what a symptom change should trigger. If a device is fitted, obtain written follow-up and alert instructions, including information for other clinicians. NHLBI arrhythmia treatment.

This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.

Animal and in-vitro evidence

Cell and animal experiments on vessel function or cardiac stress can suggest mechanisms. They do not establish safe human dosing, symptom improvement or fewer serious events. A laboratory preparation and a retail product may differ in composition, absorption and exposure. No animal or in-vitro result contributes to the independent clinical verdict in this guide.

Funding and source roles

The financial stakes include ECG monitoring, electrophysiology services, antiarrhythmic medicines, implanted devices and ablation. Diagnostic yield, symptom relief and prevention of a serious event are distinct claims. No commercially supported efficacy result establishes the independent verdict in this guide.

The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.

Frequently asked questions

Is heart block a blocked artery?
No. AV block concerns electrical communication. NHLBI conduction disorders.

Are all degrees equally serious?
No. The degree and clinical context matter. NHS heart block.

Can it be intermittent?
Selected recording can help investigate intermittent electrical findings and symptoms. NHLBI arrhythmia diagnosis.

Must every finding lead to a pacemaker?
No uniform rule follows; severity and the established indication determine the plan. NHS heart block.

Sources and funding notes

• NHS heart block — Degrees, symptoms and attributed care.
• NHLBI conduction disorders — AV block versus sinus-node and bundle-branch problems.
• NHLBI arrhythmia diagnosis — ECG and intermittent recording roles.
• NHLBI arrhythmia causes — Contributing conditions and medicines.
• NHLBI arrhythmia treatment — Pacing and emergency-care framework.
• NHS arrhythmia — Urgent associated symptoms.
• NHLBI arrhythmias — Additional original linked in condition-specific education or follow-up.
• NHLBI living with arrhythmia — Additional original linked in condition-specific education or follow-up.
• NHLBI budget — Financial provenance only.
• NHLBI Gift Fund — Financial provenance only.
• NHS national website funding policy — Financial provenance only.

Original clinical pages and their relevant financial disclosures were opened. Where cited, the 2026 definition was read through the web tool; its author supplement was inaccessible and remains an explicit gap. Where cited, the 2018 SCAD papers were read in original full versions, including funding and disclosure tables. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.

Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.